Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 59.81
-0.42 (-0.70%)
Apr 29, 2026, 3:00 PM CST
SHA:603087 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Cash & Equivalents | 2,165 | 2,088 | 902.78 | 2,443 | 2,890 | 3,306 | Upgrade
|
| Short-Term Investments | - | - | - | - | 201.36 | 276.44 | Upgrade
|
| Trading Asset Securities | 1,251 | 1,401 | 1,500 | 2,410 | 1,636 | 1,624 | Upgrade
|
| Cash & Short-Term Investments | 3,416 | 3,489 | 2,403 | 4,853 | 4,728 | 5,206 | Upgrade
|
| Cash Growth | 44.96% | 45.20% | -50.48% | 2.66% | -9.20% | 14.24% | Upgrade
|
| Accounts Receivable | 447.85 | 599.87 | 213.71 | 383.74 | 189.57 | 934.66 | Upgrade
|
| Other Receivables | 5.82 | 3.76 | 31.89 | 1.63 | 0.99 | 0.16 | Upgrade
|
| Receivables | 453.67 | 603.63 | 245.6 | 385.37 | 190.55 | 934.82 | Upgrade
|
| Inventory | 1,090 | 1,009 | 1,053 | 860.51 | 648.65 | 651.33 | Upgrade
|
| Other Current Assets | 442.44 | 382.32 | 89.07 | 76.73 | 97.36 | 77.95 | Upgrade
|
| Total Current Assets | 5,403 | 5,484 | 3,791 | 6,176 | 5,664 | 6,870 | Upgrade
|
| Property, Plant & Equipment | 3,514 | 3,577 | 3,882 | 3,886 | 3,661 | 2,595 | Upgrade
|
| Long-Term Investments | 479.31 | 520.53 | 497.03 | 304.66 | 30 | 201.36 | Upgrade
|
| Other Intangible Assets | 509.39 | 265.11 | 273.06 | 278.08 | 293.48 | 295.99 | Upgrade
|
| Long-Term Deferred Tax Assets | 220.36 | 213.67 | 206.94 | 168.95 | 138.25 | 30.8 | Upgrade
|
| Long-Term Deferred Charges | 1,579 | 1,611 | 924.91 | 821.97 | 743.19 | 588.87 | Upgrade
|
| Other Long-Term Assets | 974.67 | 954.72 | 2,468 | 79.99 | 76.51 | 270.33 | Upgrade
|
| Total Assets | 12,680 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 | Upgrade
|
| Accounts Payable | 147.71 | 134.41 | 115.61 | 94.82 | 36.52 | 26.15 | Upgrade
|
| Accrued Expenses | 156.97 | 187.26 | 183.44 | 192.54 | 190 | 173.04 | Upgrade
|
| Current Portion of Long-Term Debt | 8.27 | 8.99 | - | - | - | - | Upgrade
|
| Current Portion of Leases | - | - | 1.33 | 2.18 | 5.69 | 5.07 | Upgrade
|
| Current Income Taxes Payable | 34.4 | 50.87 | 1.49 | 1.42 | 1.35 | 106.32 | Upgrade
|
| Current Unearned Revenue | 54.96 | 67.88 | 63.25 | 52.99 | 68.13 | 36.56 | Upgrade
|
| Other Current Liabilities | 274.22 | 366.37 | 436 | 429.49 | 511.36 | 138.39 | Upgrade
|
| Total Current Liabilities | 676.53 | 815.79 | 801.13 | 773.45 | 813.04 | 485.53 | Upgrade
|
| Long-Term Leases | 2.27 | 2.54 | 3.31 | 5.45 | 8.33 | 12.17 | Upgrade
|
| Long-Term Unearned Revenue | 169.9 | 170.75 | 168.92 | 179.63 | 187.63 | 141.98 | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | 12.11 | - | - | 36.15 | Upgrade
|
| Other Long-Term Liabilities | 2.96 | 9.5 | 2.97 | 14 | 12.27 | 10.2 | Upgrade
|
| Total Liabilities | 851.65 | 998.57 | 988.45 | 972.52 | 1,021 | 686.02 | Upgrade
|
| Common Stock | 597.3 | 597.3 | 601.07 | 594.16 | 565.65 | 561.54 | Upgrade
|
| Additional Paid-In Capital | 3,539 | 3,534 | 3,591 | 3,351 | 2,563 | 2,476 | Upgrade
|
| Retained Earnings | 7,798 | 7,606 | 7,059 | 6,865 | 6,525 | 7,133 | Upgrade
|
| Treasury Stock | -111.17 | -111.17 | -200.85 | -71.36 | -71.36 | - | Upgrade
|
| Comprehensive Income & Other | 2.5 | 3.06 | 4.04 | 3.82 | 3.44 | -3.44 | Upgrade
|
| Total Common Equity | 11,826 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 | Upgrade
|
| Minority Interest | 1.98 | - | - | 0 | -0.16 | -0.16 | Upgrade
|
| Shareholders' Equity | 11,828 | 11,628 | 11,054 | 10,743 | 9,586 | 10,167 | Upgrade
|
| Total Liabilities & Equity | 12,680 | 12,627 | 12,043 | 11,715 | 10,607 | 10,853 | Upgrade
|
| Total Debt | 10.54 | 11.53 | 4.64 | 7.62 | 14.01 | 17.24 | Upgrade
|
| Net Cash (Debt) | 3,406 | 3,478 | 2,399 | 4,846 | 4,714 | 5,189 | Upgrade
|
| Net Cash Growth | 44.70% | 45.00% | -50.50% | 2.80% | -9.16% | 13.86% | Upgrade
|
| Net Cash Per Share | 5.76 | 5.87 | 4.06 | 8.55 | 8.37 | 9.25 | Upgrade
|
| Filing Date Shares Outstanding | 583.29 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 | Upgrade
|
| Total Common Shares Outstanding | 583.29 | 591.12 | 598.96 | 590.05 | 561.54 | 561.54 | Upgrade
|
| Working Capital | 4,726 | 4,668 | 2,990 | 5,402 | 4,851 | 6,385 | Upgrade
|
| Book Value Per Share | 20.27 | 19.67 | 18.46 | 18.21 | 17.07 | 18.11 | Upgrade
|
| Tangible Book Value | 11,317 | 11,363 | 10,781 | 10,464 | 9,292 | 9,871 | Upgrade
|
| Tangible Book Value Per Share | 19.40 | 19.22 | 18.00 | 17.73 | 16.55 | 17.58 | Upgrade
|
| Buildings | - | - | 2,137 | 1,344 | 1,165 | 1,046 | Upgrade
|
| Machinery | - | - | 1,601 | 1,443 | 1,237 | 1,263 | Upgrade
|
| Construction In Progress | - | - | 1,262 | 2,007 | 2,003 | 874.91 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.